TrialNature communications2023

Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.

Ivan T Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.